Iruplinalkib

CAS No. 1854943-32-0

Iruplinalkib( —— )

Catalog No. M35759 CAS No. 1854943-32-0

Iruplinalkib (WX-0593) is an orally active, selective and potent ALK and ROS1 tyrosine kinase inhibitor with anticancer activity for use in the study of non-small cell lung cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 117 Get Quote
10MG 188 Get Quote
25MG 419 Get Quote
50MG 634 Get Quote
100MG 888 Get Quote
500MG 1782 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Iruplinalkib
  • Note
    Research use only, not for human use.
  • Brief Description
    Iruplinalkib (WX-0593) is an orally active, selective and potent ALK and ROS1 tyrosine kinase inhibitor with anticancer activity for use in the study of non-small cell lung cancer.
  • Description
    Iruplinalkib (WX-0593) is a potent, selective, and orally active inhibitor of ALK and ROS1 tyrosine kinase. Iruplinalkib (WX-0593) shows favorable safety and promising antitumor activity in advanced NSCLC with ALK or ROS1 rearrangement.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    ALK
  • Recptor
    ALK | ROS Kinase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1854943-32-0
  • Formula Weight
    569.08
  • Molecular Formula
    C29H38ClN6O2P
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 10 mg/mL (17.57 mM; Ultrasonic (<60°C)
  • SMILES
    O=P(C=1C=CC=CC1NC2=NC(=NC=C2Cl)NC3=CC=C(C=C3OC)N4CCC5(CC4)CCN(C)CC5)(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Shi Y, et al. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022;7(1):25. ?
molnova catalog
related products
  • INCB-000928

    Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.

  • CEP-28122

    A highly potent and selective, orally active ALK inhibitor with IC50 of 1.9 nM.

  • AZD3463

    AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.